Discovering and Developing Biomarkers for Acute Conditions.

Astute Medical, a bioMérieux Company, is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers.

In particular, Astute developed the NephroCheck^® Test for the early risk assessment of acute kidney injuries (AKI) based on the level of two biomarkers, IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) and TIMP-2 (Tissue Inhibitor Metalloproteinases-2).